Robots have taken over Los Angeles. It’s not just the AI-generated videos that have caused angst in Hollywood. Our streets are full of driverless Waymo vehicles, covered in more sensors and gadgets than the Batmobile. And our walkways are home to fleets of boxes on wheels, hurrying past pedestrians and navigating outdoor bar-hoppers as the robots deliver smoothies and keto-friendly salads. And it’s only getting stranger. This month, Serve Robotics, one of the leading companies behind the food-delivery bots, deployed another 500 of them in 40 neighborhoods across the city, up from two neighborhoods in 2023. The other big company, Coco Robotics, founded at UCLA in 2020, has about 300 robots across the city and is looking to expand. Soon a region already known for its lack of walkability will have more obstacles for pedestrians to contend with. View image in fullscreen A delivery robot in West Hollywood on 19 March 2024. Photograph: Mario Tama/Getty Images The expansion has sparked consternation in LA and other US cities as residents debate whether our new neighbors are welcome. Neighboring Glendale is considering a moratorium on the bots; Chicago has also limited their expansion. Worse than the sidewalk frustrations, they mean fewer jobs for delivery drivers, even if some are human-controlled. On the flip side, they don’t emit exhaust fumes or add to road traffic. And when they’re not accidentally smashing the glass on bus shelters, they achieve R2-D2 levels of cuteness, manipulating us with little nametags and blinking digital eyes. Is resisting the robots simply denying the future of food delivery? Inspiring ‘both pity and hate’ On a recent Tuesday, workers and residents along Thoroughfare XJ-27, known to humankind as Sunset Blvd, described mixed feelings about the bots. In the Silverlake neighborhood, for instance, where many drinking and dining establishments seat people along the sidewalk, the devices can be disruptive. Pazzo Gelato, a longstanding gelato and cof...

The invitation thumps on to your doormat – or, as likely, into your inbox – and rather than feel excitement for the ensuing nuptials, you feel dread. What on earth to wear? The Guardian’s journalism is independent. We will earn a commission if you buy something through an affiliate link. Learn more. Weddings are full of sartorial pitfalls. If there’s no dress code, the limitless options can feel daunting; if there is, it can feel a different kind of daunting, but with a useful guide to prevent you from feeling overwhelmed. The trick, dress code or not, is to make an effort – never flip-flops, for instance. If the invitation calls for black tie, stick to as close to floor-length as you can with a fabric that denotes formality, such as silk or velvet, depending on the season. For a destination wedding, which often translates to “somewhere hot”, be mindful of fabrics and what your hosts may have been hoping for when they planned Mykonos over rural Shropshire, and apply that to your wardrobe. Breezy linen and cotton are smarter than sweaty polyester (this bold red linen dress or this similar, shorter style would be winners). If it’s a beach wedding, why not lean into the holiday atmosphere with unexpected colour combinations, prints or the kinds of accessories that might look odd in a field but fun on a beach? Think night out on holiday, but turned up. For a quaint countryside wedding, you may need a fancy layer for evening chill – that doesn’t have to mean a pashmina in 2026. In fact, it probably shouldn’t. Would a fancy blouse work? Or could you lean into the current trend for tying a silk scarf around everything and transition one from your bag or waist to around your shoulders when it gets nippier? Secondhand sites, such as Vinted, and charity shops are your friend here. Get your footwear right – remember, spiky heels sink into grass. Ballet flats have been around the block for enough years now that there are some fun iterations out there, such as these from Hai (in...

The era when the three joint communiques set the terms of US-China relations may have “completely come to an end”, a prominent Chinese analyst has warned. Zhu Feng, dean of Nanjing University’s School of International Studies, also said that it might be “unrealistic” to expect Beijing and Washington to reach a comprehensive political understanding on Taiwan, given US domestic politics. Following Chinese President Xi Jinping’s highly anticipated summit with US counterpart Donald Trump earlier this month, Beijing announced that the leaders had agreed to build a “constructive relationship of strategic stability”, calling it a major milestone. Advertisement The White House later echoed the phrase, adding that it should operate “on the basis of fairness and reciprocity”. 01:56 ‘A milestone visit’: Xi and Trump set sights on stability for China-US relations According to Zhu, this demonstrated a mutual effort to align their perceptions and policy frameworks, effectively laying fresh groundwork for future ties.

Last week, a federal court ruled against Elon Musk in a multi-billion-dollar lawsuit he filed against OpenAI ( OPENAI ) and its largest investor, Microsoft ( MSFT ), over the company's conversion from a nonprofit to a for-profit entity. Despite OpenAI's apparent win, the ChatGPT developer is still facing lawsuits filed by Musk's AI company, xAI, over alleged trade secret theft and anticompetitive practices. XAI ( X.AI ) is now a division of SpaceX ( SPCX ), which is expected to hold a massive IPO later this year. We asked Seeking Alpha analysts Oliver Rodzianko and Michael Del Monte what they thought lay ahead for OpenAI, which is also expected to go public this year. Oliver Rodzianko : I think Musk is using litigation as a competitive friction tool against OpenAI ( OPENAI ), converting a backward-looking founder grievance into present-day tactical pressure on a direct competitor. Even without winning, repeated legal attacks can increase management distraction, discovery risk, reputational noise, and investor diligence questions around the OpenAI IPO. However, the strategy cuts both ways, as it also consumes Musk’s time, xAI’s ( X.AI ) resources, and public credibility if courts keep demanding harder evidence. Musk is unlikely to stop, though, with the fight seemingly shifting toward appeal, trade-secret claims, antitrust framing, and public pressure. This entanglement is likely a distraction for both parties away from what matters most now, which is responsibly scaling AI and ensuring the investment cycle is accretive to end customers in a broad-based manner, rather than largely consumptive. Michael Del Monte : While OpenAI ( OPENAI ) remains as the face of the AI revolution, I believe that the developer has fallen behind Anthropic ( ANTHRO ) in terms of capabilities and functionality. With Anthropic targeting enterprise-grade customers, the company’s models have become embedded for their deeper capabilities and functionality, particularly with high-growth platform...

If you bought JPMorgan Nasdaq Equity Premium Income ETF (NASDAQ:JEPQ) for the monthly checks, you probably think you own a Nasdaq-100 portfolio with a covered-call overlay. That is mostly true. The part that gets less airtime is that JEPQ’s option exposure runs through equity-linked notes, which are unsecured debt of the banks that issue them. ... JEPQ’s Distribution Looks Like Income Until You See the ELN Counterparty Risk Behind It

A trader who bought ProShares UltraPro QQQ (NASDAQ:TQQQ) at the start of 2022 expecting the tech rally to continue ended the year down roughly 80%, while the Nasdaq 100 fell about 34%. That gap is the entire argument against treating TQQQ as a buy-and-hold position. The fund did exactly what its prospectus promised on a ... TQQQ’s 3x Promise Quietly Cost Holders 81 Percent in 2022 While the Nasdaq Fell Just 33 Percent

Five days. That’s all that’s left to lock in one of the smartest advantages you can give yourself as a founder, investor, or operator right now. Early Bird savings for TechCrunch Disrupt 2026 end May 29 at 11:59 p.m. PT. Register now to save up to $410 before prices increase and secure your spot at the center of the startup ecosystem. Winning as a startup isn’t just about pitching Advancing from idea to IPO takes time and how you spend that time can make the difference in whether you stall or scale. Many think it’s the pitch that slows things down. But in reality, it’s access. Fundraising is a long game of chasing proximity. Cold outreach. Missed intros. Weeks waiting for replies that never come. You spend as much time trying to get in front of the right investors as you do refining your story. Without access, capital is moving. Deals are getting done. Just not with you. When Disrupt comes to Moscone West in San Francisco, October 13–15, 2026, access isn’t accidental because it’s built into the experience. Those who attend can access: Startup Battlefield 200: Pitch in front of top-tier VCs and compete for a $100,000 equity-free prize. Deal Flow Café: A dedicated space for real investor-founder conversations. Curated matchmaking: Targeted 1:1 and small-group meetings with aligned investors. Expo Hall proximity: Turn cold outreach into live demos and real conversations. You shift from chasing attention to securing influence Your Disrupt ticket gives you access to candid, tactical, and unfiltered insights from active founders, top-tier investors, and operators scaling real companies like: Image Credits:Kimberly White / Getty Images Explore the sessions these tech leaders will lead on the agenda page. And register before May 29 at 11:59 p.m. PT to save up to $410 and show up with more opportunities to connect, fundraise, and scale. This is where fundraising cycles compress When Disrupt hits San Francisco, more than 10,000 founders, investors, and operators, along with 3...

Ever since Big Tech went all in on artificial intelligence more than three years ago, seven companies have done the heavy lifting for overall S&P 500 earnings growth. But more recently, the other 493 names in the index have started to pull their weight.

Major earnings expected during the late afternoon on Monday FinVolution Group ( FINV ) JOYY ( JOYY ) For Seeking Alpha's full earnings season calendar, click here .

Pentagon Conducts First Military Drill In Venezuela Since Maduro Overthrow On Saturday, the US military conducted a highly visible drill right in the heart of Caracas, marking the first known American military exercise on Venezuelan soil since the chaotic January 3rd operation to abduct Venezuelan President Nicolas Maduro . The show of force involved two US Marine Corps Osprey aircraft touching down near the recently reopened US Embassy in Caracas , which went operational only two months ago, in March. via Reuters "The drill, which the Venezuelan government said it had authorized as an evacuation drill for possible medical emergencies or disasters , included two MV-22B ​Osprey aircraft that landed near the U.S. embassy and vessels that entered Venezuelan ​waters in the Caribbean Sea," Reuters detailed . Venezuela's Foreign Minister Yván Gil had announced and previewed the drill to the local population, and dubbed the action a 'rapid response' exercise in the heart of the capital. There were reports of protests in the capital , by those who reject their country being used for American military drills : While some Caracas residents gathered to observe the aircraft, a group of protesters elsewhere in the city displayed a Venezuelan flag with the message 'No to the Yankee drill' to express their opposition . However, other crowds reportedly gathered just the watch the large Marine Corps Ospreys sweep in low to the city. The US Embassy later revealed that Gen. Francis L. Donovan, the head of US Southern Command, was personally on board one of the Ospreys. This marks Donovan's second high-profile visit to Caracas since the January raid, which left a bloody trail of at least 83 dead - mostly Venezuelan military forces, Cuban presidential guards, but also reportedly four civilians. According to an official post on X by the US Embassy, Donovan's itinerary made for a busy day: "[Donovan] participated in bilateral talks with high-ranking representatives of the interim governme...

Bill Ackman is one of the most followed investment managers in the market today, and for good reason. His Pershing Square Holdings fund has produced annualized returns of 14.9% from its founding in 2004 through 2025 based on its stock price, handily beating the S&P 500 in that time. Meanwhile, Greg Abel is better known for his managerial acumen than for his investing chops. Nonetheless, he's now in charge of Berkshire Hathaway's (BRKA +1.43%) (BRKB +1.32%) massive $330 billion equity portfolio (with an extra $380 billion in cash on the sidelines). The two found themselves on opposite sides of a trade last quarter. While Abel was adding to Berkshire's position in Alphabet (GOOG 1.04%) (GOOGL 1.19%), Ackman was selling the shares he'd held since 2023. Ackman completed selling all of Pershing Square's Alphabet shares in April; meanwhile, the stock is suddenly Berkshire's fifth-largest position, representing a significant bet from Abel. Which investment manager should readers follow? The full-stack artificial intelligence company Alphabet has long been a leading innovator in artificial intelligence (AI), and it now finds itself in a position where it's monetizing those efforts across multiple layers of the AI value chain. Its Google Cloud business rents compute capacity to developers, providing access to AI services that enable developers to build on top of foundation large language models. It sells access to popular AI accelerator chips, including its own Tensor Processing Units (TPUs) and central processing units (CPUs). Alphabet has even started selling its TPUs to third-party data centers. It also develops the Gemini family of models, which are among the most performant on the market. It's seen strong adoption, including a contract with Apple to use Gemini as the foundation for its revamped Siri, expected to launch this year. The third level of the stack is its own products. Alphabet has integrated generative artificial intelligence into Search, Chrome, and its ad p...

美國總統特朗普表示，與伊朗的談判進展順利，但如果達不成協議，便回到交火狀態，但規模會比以往更大。伊朗部就指重點是結束戰事，雙方已就大部分問題達成共識，但不意味即將簽署協議。 正訪問印度的美國國務卿魯比奧，周一參觀世界文化遺產泰姬陵。參觀前他提到，美國和伊朗的談判仍在進行，可能有新進展。 美國國務卿魯比奧說：「我們目前有一個較確定的方案，有能力讓(霍爾木茲)海峽開放，進入一場非常真實、重要且限時的核問題談判。正如總統(特朗普)所說，他不急，他不會達成不利的交易。」 魯比奧又強調，美方在不得不考慮其他選項前，會盡最大努力以外交手段解決問題。 特朗普周日在社交平台兩度發文，改口指美伊協議尚未完全談妥，談判正有序進行，並強調一旦達成，將會是一份好和合適的協議，但在未達成協議前，美方維持對伊朗的海上封鎖。 英國《金融時報》報道，在美伊接近達成協議消息傳出後，共和黨內有鷹派參議員不滿協議對伊朗讓步過多，導致特朗普改口風。 伊朗外交部發言人巴加埃表示，目前與美國談判的14點諒解備忘錄，重點是結束戰事，內容包括結束黎巴嫩在內所有戰線的戰爭、美軍結束對伊朗的海上封鎖；作為交換，伊朗將採取措施，確保霍爾木茲海峽通行安全，雙方已就大部分問題達成共識，但不意味即將簽署協議。 發言人又補充，霍爾木茲海峽的管理權屬沿岸國家，不會在與美方的諒解備忘錄中，討論海峽管理權的具體細節。若最終達成諒解備忘錄框架，其細節和核問題等議題，將在60天內協商。 在北京，外交部指，美伊近期通過談判解決問題，受到國際社會歡迎。 外交部發言人毛寧表示：「對話的大門既然打開，就不應當再次關上，應當穩住局勢的緩和勢頭，堅持政治解決的大方向，通過對話協商，達成兼顧各方關切的解決方案。」 發言人又呼籲盡快重開航道，達成全面持久停火，令中東海灣局勢恢復和平穩定。

永川茶山竹海街道24日2时至4时最大雨量达到296.6毫米、最大小时雨量103.6毫米。大桥村发生山体滑坡，有村民被掩埋，工作人员称出事位置并不在几个重要的地质灾害点 2026年5月25日，重庆永川，救援人员在永川茶山竹海街道大桥村受灾点开展搜救工作。图：何蓬磊/中新社视觉中国 【财新网】 强降雨持续影响全国多地，并造成人员伤亡。5月23日夜间至24日凌晨，重庆市永川区突发瞬时极端特大暴雨引发山洪和地质灾害，辖区茶山竹海街道、中山路街道、双石镇等多地出现散点式灾情。据央视新闻消息，截至25日15时30分，共导致9人死亡，11人失联。 财新了解到，在此次暴雨山洪和地质灾害中，茶山竹海街道大桥村发生滑坡，有村民被掩埋。大桥村村委会一名唐姓工作人员告诉财新，滑坡发生在凌晨，当时风大雨大，“山体滑下来的时候，看不到，也听不到”，直到天亮才看清现场的情况。对于大桥村到底有几户多少人被掩埋，其未肯透露。

Richard Drury/DigitalVision via Getty Images iShares Morningstar Value ETF ( ILCV ) is a diversified value-focused security with a portfolio of 381 large- and mid-cap stocks. ILCV has the potential to deliver a mid-teen percentage share price appreciation in 2026, in-line with its three-year average return of 16%. The fund’s dividend yield of 1.68% can also contribute a small percentage to its total returns. Its expense ratio of 0.04% appears low, while the liquidity is in-line with the median of all ETFs. On the negative side, the ETF is likely to underperform in 2026 compared to the S&P 500 and growth category due to the tech-driven bullish conditions. Despite that, ILCV appears to be a solid candidate for investors seeking to enhance portfolio stability. It could also be a worthwhile investment vehicle for value investors to gain exposure to a portfolio of large-mid cap value stocks through a single investment. Therefore, I initiate coverage of ILCV with a buy rating. ILCV Performance Review and Potential Upside ILCV returns (ishares.com) In the past three years, iShares Morningstar Value ETF has delivered a solid average price return of nearly 16% compared to its 5 and 10-year average of 11%. I believe ILCV’s share price has the potential to generate a mid-teen percentage price growth in 2026, driven by its well-balanced sector exposure and large number of portfolio holdings. The fund tracks the performance of both large and mid caps. While the large caps are likely to benefit from their robust earnings growth power, the mid caps can also contribute to its performance in a low rate environment. According to the FactSet data , the bottom-up 2026 price target for the S&P 500 is 8600, reflecting a 23% surge for the full-year and a 15% increase from the current level. Given ILCV’s beta of 0.79, the ETF has the potential to deliver a mid-teen percentage price appreciation in 2026. Year-to-date, ILCV’s share price is up 6.5%. The S&P 500 and ILCV’s price upside prospe...

PM Images/DigitalVision via Getty Images Highlights In the first quarter, economic growth and solid corporate earnings eventually gave way to concern about geopolitical turmoil, a possible bubble in AI spending, and rising energy costs. The fund's equities outperformed due to an overweight in the strong-performing energy sector, as well as stock picking in information technology and consumer discretionary. Security selection in consumer staples and industrials modestly detracted. The fund's fixed-income securities underperformed, primarily reflecting unfavorable yield curve positioning. Security selection contributed to performance. Market review and outlook In Q1, continued economic growth and better-than-expected corporate earnings were often overshadowed by geopolitics, leading to a weak U.S. equity market. Concerns about a possible bubble in AI spending and rising energy costs triggered large price swings in certain stocks, even as the market's overall volatility was constrained. Meanwhile, U.S. bonds produced mixed results. Although the U.S. Federal Reserve (Fed) held short-term interest rates steady, geopolitical uncertainty led to revised expectations for Fed interest rate policy. Instead of anticipating one or two interest rate cuts in 2026, investors began pricing in a rate increase before year-end. In this environment, U.S. bond yields moved higher. Looking ahead, given the challenging geopolitical climate, we expect the Fed to take a cautious approach to future interest rate decisions. Meanwhile, after a downturn, stock valuations now strike us as a bit more reasonable. The combination of more favorable pricing and periodic big market swings presents what we believe to be a strong environment for bottom-up security selection. Contributors and detractors The fund's equity portfolio significantly outperformed. Asset positioning, specifically overweights in the energy and materials sectors driven by our security-selection process, was the largest positive dr...

格隆汇5月25日｜据央视财经，近日，6GHz频段获工业和信息化部批复，这让我国成为全球首个批复6G试验频率使用许可的国家。在此次许可批复后，6G技术研发将从实验室仿真、室内样机测试环节，逐步走向城市、工业等真实场景中完成性能验证。从推进节点来看，2022-2025年，我国已顺利完成第一阶段6G关键技术试验，当前正在启动第二阶段技术方案试验。未来，国际层面还需完成首版6G标准的制定。业内普遍预计，6G有望在2030年前后正式商用。

当地时间25日，俄罗斯外交部发布通报称，俄军将对乌克兰首都基辅的军工联合体发动一系列打击，打击将针对决策中心与指挥所。俄方警告外国公民尽快离开基辅市，并呼吁基辅市民不要靠近乌克兰军事和行政基础设施。当天，乌克兰空军发言人伊格纳特发出预警，称俄罗斯正计划对基辅发动高强度空袭，而乌克兰目前弹道防空导弹储备严重不足，防御形势承压。（央视新闻）

格隆汇5月25日｜据央视财经，巴西马托格罗索州是全球重要的肉牛养殖产区，凭借优越的自然条件，当地牛肉产业规模长期位居巴西首位。受中东战事影响，当地牧场养殖成本大幅攀升，牛肉产业遭遇严峻挑战。马托格罗索州位于巴西内陆，牛肉出口的物流成本本就偏高。受近期中东地缘冲突影响，柴油价格持续上涨，进一步推高了当地牛肉出口成本。 此外，中东地区是当地重要外销市场。目前中东部分地区海运航线受阻、海运保险费用大幅攀升，直接削弱巴西牛肉的出口竞争力。根据巴西肉类出口工业协会的数据，巴西对中东地区的牛肉出口已连续2个月出现下滑。专家表示，出口受挫，给该州肉牛全产业链造成的负面影响不容小觑。

(RTTNews) - Monday, Freehold Royalties Ltd. (FRU.TO) announced that the Toronto Stock Exchange has accepted the company's notice of intention to renew its normal course issuer bid, allowing it to buy about 10 percent of its issued and outstanding shares as of May 14, 2026. The Renewed NCIB, expected to begin on May 27, 2026, will end on the earliest of the following dates: (i) when the company buys back all the Shares it plans to acquire under the Renewed NCIB; or (ii) May 26, 2027, unless the company decides to end the program earlier by giving prior notice to the TSX. Under its current NCIB, which expires on May 26, 2026, the company sought approval from the TSX to purchase up to 13,699,733 shares. Currently, Freehold's stock is trading at C$17.52, down 0.40 percent on the Toronto Exchange. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

格隆汇5月25日｜溧阳中联金硫磺最新价格6856元/吨，环比上一工作日下行228元/吨，消息面再度动摇市场心态，美伊协议与船只动态使得部分从业者调整对供应恢复的预期，价格大幅下行。传统化肥买家强烈抵制高价，多选择降低开工率或转向直接进口DAP，金属行业买家仍有采购意向，预计短期价格将维持高位。中国市场来看，4月5月进口量不断降低，港口库存接近历史低位，短期地缘脱敏，行情波动幅度降低，建议从业人员理性操作，国内区间参考7000-8000元/吨。

Nuvectis Pharma, Inc. (NVCT) closed the last trading session at $10.35, gaining 16.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $16.25 indicates a 57% upside potential. The mean estimate comprises four short-term price targets with a standard deviation of $4.35. While the lowest estimate of $10.00 indicates a 3.4% decline from the current price level, the most optimistic analyst expects the stock to surge 93.2% to reach $20.00. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable. However, an impressive consensus price target is not the only factor that indicates a potential upside in NVCT. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside. Price, Consensus and EPS Surprise Here's What You May Not Know About Analysts' Price Targets According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading. While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitiv...

Willdan Group (WLDN) closed the last trading session at $93.55, gaining 20% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $130 indicates a 39% upside potential. The mean estimate comprises three short-term price targets with a standard deviation of $18.03. While the lowest estimate of $110.00 indicates a 17.6% increase from the current price level, the most optimistic analyst expects the stock to surge 55% to reach $145.00. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable. But, for WLDN, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside. Price, Consensus and EPS Surprise Here's What You Should Know About Analysts' Price Targets According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading. While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and...

Atlassian (TEAM) closed the last trading session at $85.42, gaining 19.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $127.92 indicates a 49.8% upside potential. The mean estimate comprises 25 short-term price targets with a standard deviation of $40. While the lowest estimate of $95.00 indicates an 11.2% increase from the current price level, the most optimistic analyst expects the stock to surge 245.4% to reach $295.00. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice. However, an impressive consensus price target is not the only factor that indicates a potential upside in TEAM. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside. Price, Consensus and EPS Surprise Here's What You Should Know About Analysts' Price Targets According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading. While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivi...

Viavi Solutions (VIAV) closed the last trading session at $49.51, gaining 3.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $64.63 indicates a 30.5% upside potential. The mean estimate comprises eight short-term price targets with a standard deviation of $3.54. While the lowest estimate of $60.00 indicates a 21.2% increase from the current price level, the most optimistic analyst expects the stock to surge 41.4% to reach $70.00. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice. But, for VIAV, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside. Price, Consensus and EPS Surprise Here's What You May Not Know About Analysts' Price Targets According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading. While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business ...

Biodesix, Inc. (BDSX) closed the last trading session at $14.93, gaining 40.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $30.5 indicates a 104.3% upside potential. The mean estimate comprises four short-term price targets with a standard deviation of $7.37. While the lowest estimate of $22.00 indicates a 47.4% increase from the current price level, the most optimistic analyst expects the stock to surge 167.9% to reach $40.00. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable. However, an impressive consensus price target is not the only factor that indicates a potential upside in BDSX. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside. Price, Consensus and EPS Surprise Here's What You May Not Know About Analysts' Price Targets According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading. While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivit...

Lifezone Metals Limited (LZM) closed the last trading session at $5.09, gaining 0.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $8.63 indicates a 69.6% upside potential. The mean estimate comprises three short-term price targets with a standard deviation of $2.01. While the lowest estimate of $7.00 indicates a 37.5% increase from the current price level, the most optimistic analyst expects the stock to surge 113.8% to reach $10.88. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable. But, for LZM, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside. Price, Consensus and EPS Surprise Here's What You May Not Know About Analysts' Price Targets According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading. While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to e...

Alliance Laundry Holdings (ALH) closed the last trading session at $24.77, gaining 2.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $31.29 indicates a 26.3% upside potential. The mean estimate comprises seven short-term price targets with a standard deviation of $3.04. While the lowest estimate of $27.00 indicates a 9% increase from the current price level, the most optimistic analyst expects the stock to surge 49.4% to reach $37.00. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice. However, an impressive consensus price target is not the only factor that indicates a potential upside in ALH. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside. Price, Consensus and EPS Surprise Here's What You May Not Know About Analysts' Price Targets According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading. While Wall Street analysts have deep knowledge of a company's fundamentals and t...

Carlsmed, Inc. (CARL) closed the last trading session at $12.11, gaining 18.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $18.4 indicates a 51.9% upside potential. The average comprises five short-term price targets ranging from a low of $16.00 to a high of $23.00, with a standard deviation of $2.7. While the lowest estimate indicates an increase of 32.1% from the current price level, the most optimistic estimate points to a 89.9% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice. However, an impressive consensus price target is not the only factor that indicates a potential upside in CARL. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside. Price, Consensus and EPS Surprise Here's What You May Not Know About Analysts' Price Targets According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading. While Wall Street analysts have deep knowledge of a company's fu...

Shares of Afya (AFYA) have gained 0.2% over the past four weeks to close the last trading session at $14, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $17.58 indicates a potential upside of 25.6%. The mean estimate comprises six short-term price targets with a standard deviation of $3.26. While the lowest estimate of $15.00 indicates a 7.1% increase from the current price level, the most optimistic analyst expects the stock to surge 57.1% to reach $22.00. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable. However, an impressive consensus price target is not the only factor that indicates a potential upside in AFYA. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside. Price, Consensus and EPS Surprise Here's What You Should Know About Analysts' Price Targets According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading. While Wall Street analysts have deep knowledge of a company's fu...

Adicet Bio, Inc. (ACET) closed the last trading session at $8.3, gaining 5.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $34.83 indicates a 319.6% upside potential. The average comprises six short-term price targets ranging from a low of $18.00 to a high of $100.00, with a standard deviation of $32.12. While the lowest estimate indicates an increase of 116.9% from the current price level, the most optimistic estimate points to an 1104.8% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice. However, an impressive consensus price target is not the only factor that indicates a potential upside in ACET. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside. Price, Consensus and EPS Surprise Here's What You Should Know About Analysts' Price Targets According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading. While Wall Street analysts have deep knowledge of a compan...